Selenium Levels in Patients With Abdominal Aneurysm

NCT ID: NCT07236281

Last Updated: 2025-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-15

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Retrospective study comparing the selenium level in patients with abdominal aortic aneurysm with the selenium level in patients in the control group, i.e., patients without aneurysmal changes of the abdominal aorta.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Selenium (Se), incorporated into selenocysteine, is an essential component of selenoproteins. These proteins play a crucial role in vascular protection by reducing oxidative stress, regulating inflammation, supporting endothelial nitric oxide signalling, and maintaining smooth muscle cell homeostasis. Insufficient selenoprotein activity contributes to vascular dysfunction and weakening of the vessel wall.

The aim of this project is to investigate a potential association between reduced selenium levels and abdominal aortic aneurysm (AAA) of degenerative origin.

The study group will include 20 individuals with an abdominal aortic aneurysm measuring at least 35 millimeters in diameter, verified by a radiologist using standard diagnostic imaging methods (ultrasound, CT angiography, or digital subtraction angiography). The control group will comprise 20 individuals without an abdominal aortic aneurysm. Selenium blood levels will be measured in both groups, and the relationship between selenium status and the presence of AAA will be evaluated using biostatistical analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Aneurysm Selenium Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cases - persons with abdominal aortic aneurysm

Persons with abdominal aortic aneurysm (AAA) of minimally 35 mm diameter, followed by vascular surgery outpatient office. AAA is verified by radiology, was not treated by surgical or endovascular intervention.

No interventions assigned to this group

Controls - persons without abdominal aortic aneurysm

Persons without abdominal aortic aneurysm (AAA), as confirmed by ultrasonography. Controls will be recruited from vascular surgery outpatient office, in treatment for other vascular conditions.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* cases - patients with AAA (confirmed by radiology) followed by vascular surgery outpatient office that signed informed consent. The AAA was not treated by surgery or endovascular intervention
* controls - people without AAA (confirmed by ultrasonography) followed by vascular surgery outpatient office for other vascular disease that signed informed consent

Exclusion Criteria

* patients that had AAA treated by surgery or endovascular intervention
* persons that did not sign informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Bratislava

OTHER

Sponsor Role collaborator

Comenius University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alexandra Brazinova

Chair of Institute of Epidemiology, Faculty of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Bratislava

Bratislava, , Slovakia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Slovakia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EK 1/11/2024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.